a Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza University of Rome , Rome , Italy.
b Pharmaceutical Chemistry, School of Pharmacy, Centre of Excellence for Pharmaceutical Sciences, North-West University , Potchefstroom , South Africa.
J Enzyme Inhib Med Chem. 2019 Dec;34(1):1511-1525. doi: 10.1080/14756366.2019.1653864.
A series of benzo[]thiophen-3-ols were synthesised and investigated as potential human monoamine oxidase (hMAO) inhibitors as well as in rat cortex synaptosomes by means of evaluation of 3,4-dihydroxyphenylacetic acid/dopamine (DOPAC/DA) ratio and lactate dehydrogenase (LDH) activity. Most of these compounds possessed high selectivity for the MAO-B isoform and a discrete antioxidant and chelating potential. Molecular docking studies of all the compounds underscored potential binding site interactions suitable for MAO inhibition activity, and suggested structural requirements to further improve the activity of this scaffold by chemical modification of the aryl substituents. Starting from this heterocyclic nucleus, novel lead compounds for the treatment of neurodegenerative disease could be developed.
一系列苯并噻吩-3-醇被合成并作为潜在的人单胺氧化酶(hMAO)抑制剂进行了研究,方法是通过评估 3,4-二羟苯乙酸/多巴胺(DOPAC/DA)比值和乳酸脱氢酶(LDH)活性。这些化合物中的大多数对 MAO-B 同工酶具有高选择性,并且具有离散的抗氧化和螯合潜力。所有化合物的分子对接研究强调了潜在的结合部位相互作用,这些相互作用适合 MAO 抑制活性,并表明通过对芳基取代基进行化学修饰,可以进一步改善该支架的活性,从而获得结构要求。从这个杂环核出发,可以开发出用于治疗神经退行性疾病的新型先导化合物。